Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant h… Read more
Liaoning Chengda Biotechnology Co. Ltd. A - Asset Resilience Ratio
Liaoning Chengda Biotechnology Co. Ltd. A (688739) has an Asset Resilience Ratio of 14.43% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Liaoning Chengda Biotechnology Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Liaoning Chengda Biotechnology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.41 Billion | 14.43% |
| Total Liquid Assets | CN¥1.41 Billion | 14.43% |
Asset Resilience Insights
- Moderate Liquidity: Liaoning Chengda Biotechnology Co. Ltd. A has 14.43% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Liaoning Chengda Biotechnology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Liaoning Chengda Biotechnology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Liaoning Chengda Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Liaoning Chengda Biotechnology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.68% | CN¥973.02 Million | CN¥10.05 Billion | -1.17pp |
| 2023-12-31 | 10.85% | CN¥1.09 Billion | CN¥10.08 Billion | -23.01pp |
| 2021-12-31 | 33.87% | CN¥3.32 Billion | CN¥9.79 Billion | +22.73pp |
| 2020-12-31 | 11.14% | CN¥501.99 Million | CN¥4.51 Billion | +8.99pp |
| 2019-12-31 | 2.15% | CN¥80.28 Million | CN¥3.74 Billion | -- |